STOCK TITAN

Ovid Therapeutics: ADAR1 reports 3.5% stake

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Ovid Therapeutics Inc. (OVID) is the issuer in an amended ownership report in which ADAR1 Capital Management, LLC and its manager Daniel Schneeberger each reported beneficial ownership of 6,703,313 shares, or 3.5% of the class, with shared voting and dispositive power. The reported amount includes 2,142,500 shares underlying warrants held by ADAR1 Partners, LP, subject to a 9.99% beneficial ownership limitation. Ovid had 188,720,929 common shares outstanding as of September 30, 2026.

Reported beneficial ownership 6,703,313 shares Reported by each reporting person as of September 30, 2026
Percent of class 3.5% Reported beneficial ownership
Shares underlying warrants 2,142,500 shares Held by ADAR1 Partners, LP as of September 30, 2026
Beneficial ownership limitation 9.99% Applies to the exchange and exercise of the warrants
Common shares outstanding 188,720,929 shares As of September 30, 2026
Shares held by ADAR1 Partners, LP 4,123,422 shares Common shares included in the reported beneficial ownership
Shares held by Spearhead Insurance Solutions IDF, LLC 435,032 shares Common shares included in the reported beneficial ownership
Shares held by other separately managed accounts 2,359 shares Common shares included in the reported beneficial ownership
beneficial ownership limitations regulatory
"exchange and exercise are subject to 9.99% beneficial ownership limitations"
Beneficial ownership limitations are rules or contractual caps that restrict how much of a company’s stock an individual or entity can be treated as owning or controlling for legal, regulatory or corporate-governance purposes. They matter to investors because such limits affect voting power, reporting obligations, takeover risk and the ability to increase a stake — like an elevator weight limit or a lane divider that prevents any one car from taking over the whole road.
shared voting power regulatory
"Shared Voting Power 6,703,313.00"
Shared voting power occurs when two or more parties jointly have the right to vote or decide how a block of company shares is cast, like co-owners who must agree before moving a piece of furniture. Investors care because who controls voting rights affects board elections, major corporate decisions and takeover outcomes, and shared control can alter regulatory disclosures and the practical influence any holder has over a company’s direction and value.
shared dispositive power regulatory
"Shared Dispositive Power 6,703,313.00"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many OVID shares did ADAR1 Capital Management report owning?

ADAR1 Capital Management, LLC and its manager Daniel Schneeberger each reported beneficial ownership of 6,703,313 shares, or 3.5% of the class, with shared voting and dispositive power.

What securities make up the reported OVID ownership?

The reported amount includes 4,123,422 shares held by ADAR1 Partners, LP, 435,032 shares held by Spearhead Insurance Solutions IDF, LLC, 2,359 shares held by other separately managed accounts, and 2,142,500 shares underlying warrants held by ADAR1 Partners, LP.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google





690469101

(CUSIP Number)
09/30/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G




Comment for Type of Reporting Person: Includes (i) 4,123,422 shares of common stock, par value $0.001 per share ("Common Stock"), held by ADAR1 Partners, LP, (ii) 435,032 shares of Common Stock held by Spearhead Insurance Solutions IDF, LLC, (iii) 2,359 shares of Common Stock held by other separately managed accounts and (iv) 2,142,500 shares of Common Stock underlying warrants held by ADAR1 Partners, LP as of September 30, 2026, the exchange and exercise of which are subject to 9.99% beneficial ownership limitations. As the investment manager of ADAR1 Partners, LP and as the sub-advisor of Spearhead Insurance Solutions IDF, LLC and the separately managed accounts referenced above, ADAR1 Capital Management, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP, Spearhead Insurance Solutions IDF, LLC and the separately managed accounts. Based on 188,720,929 shares of Common Stock of Ovid Therapeutics Inc. (the "Issuer") outstanding as of September 30, 2026, reported in the Issuer's Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2026, filed with the Securities and Exchange Commission on November 10, 2026.


SCHEDULE 13G




Comment for Type of Reporting Person: Includes (i) 4,123,422 shares of common stock, par value $0.001 per share ("Common Stock"), held by ADAR1 Partners, LP, (ii) 435,032 shares of Common Stock held by Spearhead Insurance Solutions IDF, LLC, (iii) 2,359 shares of Common Stock held by other separately managed accounts and (iv) 2,142,500 shares of Common Stock underlying warrants held by ADAR1 Partners, LP as of September 30, 2026, the exchange and exercise of which are subject to 9.99% beneficial ownership limitations. As the manager of ADAR1 Capital Management, LLC, Mr. Schneeberger may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP, Spearhead Insurance Solutions IDF, LLC and the separately managed accounts referenced above. Based on 188,720,929 shares of Common Stock of Ovid Therapeutics Inc. (the "Issuer") outstanding as of September 30, 2026, reported in the Issuer's Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2026, filed with the Securities and Exchange Commission on November 10, 2026.


SCHEDULE 13G



ADAR1 Capital Management, LLC
Signature:/s/ Daniel Schneeberger
Name/Title:Daniel Schneeberger, Manager
Date:11/16/2026
Daniel Schneeberger
Signature:/s/ Daniel Schneeberger
Name/Title:Daniel Schneeberger, in his individual capacity
Date:11/16/2026

Keep reading